Regulatory News :
Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) :
Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority):
| Date | Total number of outstanding shares | Total number of voting rights | ||
| December 31, 2014 | 40, 544, 204 |
Theoretical number of voting rights: 40, 544, 204 (including treasury shares) Number of real voting rights: 40, 528, 204 (without treasury shares) |
About Onxeo
Onxeo has the vision to become a global leader
and pioneer in oncology, with a focus on orphan or rare cancers, through
developing innovative therapeutic alternatives to “make the difference”.
The Onxeo teams are determined to develop innovative medicines to
provide patients with hope and significantly improve their lives.
Key
products at advanced development stage are:
Livatag®
(Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive®
(Clonidine Lauriad®): Positive preliminary results of the
Phase II trial in severe oral mucositis
Beleodaq® (belinostat):
registered in the US in peripheral T-cell lymphoma
For more
information, visit the website www.onxeo.com
